SIRT7缺失通过MEF2D调控PD-L1增强肝细胞癌免疫检查点抑制剂疗效
该研究探讨肝细胞癌(HCC)中MEF2D调控PD-L1表达的机制。分析20例新鲜和225例固定HCC组织,结合细胞与小鼠实验,发现MEF2D结合CD274启动子促进PD-L1转录,IFNG通过p300乙酰化MEF2D增强该过程,而SIRT7去乙酰化MEF2D抑制PD-L1;敲除SIRT7联合PD1抗体可更有效抑制肿瘤生长。
要点
- MEF2D通过结合CD274启动子促进PD-L1转录,抑制CD8+ T细胞抗肿瘤免疫。
- IFNG诱导p300结合并乙酰化MEF2D,增强PD-L1表达,不依赖IRF1/9。
- SIRT7去乙酰化MEF2D抑制PD-L1;敲除SIRT7联合PD1抗体增强疗效。
核心结论
- HCC细胞中MEF2D通过上调PD-L1抑制CD8+ T细胞介导的抗肿瘤免疫。
- IFNG通过p300乙酰化MEF2D促进其结合CD274启动子上调PD-L1。
- SIRT7去乙酰化MEF2D抑制PD-L1表达,敲除SIRT7联合PD1抗体可增强抗肿瘤效果。
研究设计与样本
- 分析20例新鲜HCC组织(流式细胞术)和225例固定HCC组织(免疫组化,来自中国2个队列)及生存数据。
- 构建肝脏特异性MEF2D敲除小鼠,在SMMC-7721、Huh7、H22、Hepa1-6细胞系中敲除或敲低MEF2D、p300或SIRT7。
- 将MEF2D敲除或对照H22细胞移植到BALB/c小鼠,部分小鼠给予抗体清除T细胞。
- 将SIRT7敲除或对照HCC细胞原位成瘤后给予PD1抗体,测量肿瘤生长并分析。
主要发现
- 人HCC标本中MEF2D水平与CD4+和CD8+ T细胞数量呈负相关,与PD1阳性或TIM3阳性CD8+ T细胞比例相关。
- H22细胞敲除MEF2D在免疫健全小鼠中肿瘤生长减慢,但在免疫缺陷或清除CD8+ T细胞的小鼠中无差异。
- MEF2D敲低或敲除降低人和小鼠HCC细胞中PD-L1表达;MEF2D结合CD274启动子并激活转录。
- IFNG暴露诱导p300表达及其与MEF2D结合,减少MEF2D与SIRT7相互作用;MEF2D诱导的PD-L1表达不依赖IRF1或IRF9。
- 未暴露IFNG时SIRT7与MEF2D形成复合物减弱PD-L1表达;敲除SIRT7的HCC细胞在免疫健全小鼠中PD-L1升高、T细胞浸润和活化减少,但给予PD1抗体后肿瘤生长慢于对照。
临床怎么用
- 干预SIRT7-MEF2D-PD-L1通路可能提高HCC免疫治疗疗效。
- MEF2D高表达或SIRT7低表达可能提示PD-L1上调及免疫抑制微环境。
- 联合PD1抗体与SIRT7抑制策略值得进一步临床前和临床研究。
局限性
- 机制研究主要基于细胞系和动物模型,人体验证有限。
- 样本来自中国2个队列,人群代表性受限。
- 未报告SIRT7或MEF2D作为生物标志物的阈值或临床干预剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune checkpoint inhibitors have some efficacy in the treatment of hepatocellular carcinoma (HCC). Programmed cell death 1 ligand 1 (PD-L1), expressed on some cancer cells, binds to the receptor programmed cell death 1 (PDCD1, also called PD1) on T cells to prevent their proliferation and reduce the antigen-tumor immune response. Immune cells that infiltrate some types of HCCs secrete interferon gamma (IFNG). Some HCC cells express myocyte enhancer factor 2D (MEF2D), which has been associated with shorter survival times of patients. We studied whether HCC cell expression of MEF2D regulates expression of PD-L1 in response to IFNG. METHODS: We analyzed immune cells from 20 fresh HCC tissues by flow cytometry. We analyzed 225 fixed HCC tissues (from 2 cohorts) from patients in China by immunohistochemistry and obtained survival data. We created mice with liver-specific knockout of MEF2D (MEF2DLPC-KO mice). We knocked out or knocked down MEF2D, E1A binding protein p300 (p300), or sirtuin 7 (SIRT7) in SMMC-7721, Huh7, H22, and Hepa1-6 HCC cell lines, some incubated with IFNG. We analyzed liver tissues from mice and cell lines by RNA sequencing, immunoblot, dual luciferase reporter, and chromatin precipitation assays. MEF2D protein acetylation and proteins that interact with MEF2D were identified by coimmunoprecipitation and pull-down assays. H22 cells, with MEF2D knockout or without (controls), were transplanted into BALB/c mice, and some mice were given antibodies to deplete T cells. Mice bearing orthotopic tumors grown from HCC cells, with or without knockout of SIRT7, were given injections of an antibody against PD1. Growth of tumors was measured, and tumors were analyzed by immunohistochemistry and flow cytometry. RESULTS: In human HCC specimens, we found an inverse correlation between level of MEF2D and numbers of CD4+ and CD8+ T cells; level of MEF2D correlated with percentages of PD1-positive or TIM3-positive CD8+ T cells. Knockout of MEF2D from H22 cells reduced their growth as allograft tumors in immune-competent mice but not in immune-deficient mice or mice with depletion of CD8+ T cells. When MEF2D-knockout cells were injected into immune-competent mice, they formed smaller tumors that had increased infiltration and activation of T cells compared with control HCC cells. In human and mouse HCC cells, MEF2D knockdown or knockout reduced expression of PD-L1. MEF2D bound the promoter region of the CD274 gene (encodes PD-L1) and activated its transcription. Overexpression of p300 in HCC cells, or knockout of SIRT7, promoted acetylation of MEF2D and increased its binding, along with acetylated histones, to the promoter region of CD274. Exposure of HCC cells to IFNG induced expression of p300 and its binding MEF2D, which reduced the interaction between MEF2D and SIRT7. MEF2D-induced expression of PD-L1 upon IFNG exposure was independent of interferon-regulatory factors 1 or 9. In HCC cells not exposed to IFNG, SIRT7 formed a complex with MEF2D that attenuated expression of PD-L1. Knockout of SIRT7 reduced proliferation of HCC cells and growth of tumors in immune-deficient mice. Compared with allograft tumors grown from control HCC cells, in immune-competent mice, tumors grown from SIRT7-knockout HCC cells expressed higher levels of PD-L1 and had reduced infiltration and activation of T cells. In immune-competent mice given antibodies to PD1, allograft tumors grew more slowly from SIRT7-knockout HCC cells than from control HCC cells. CONCLUSIONS: Expression of MEF2D by HCC cells increases their expression of PD-L1, which prevents CD8+ T-cell-mediated antitumor immunity. When HCC cells are exposed to IFNG, p300 acetylates MEF2D, causing it to bind the CD274 gene promoter and up-regulate PD-L1 expression. In addition to promoting HCC cell proliferation, SIRT7 reduced acetylation of MEF2D and expression of PD-L1 in HCC cells not exposed to IFNG. Strategies to manipulate this pathway might increase the efficacy of immune therapies for HCC.
引用
- Xiang J, Zhang N, Sun H, et al. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Gastroenterology. 2019. PMID: 31678303. doi:10.1053/j.gastro.2019.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。